Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.
Extended follow-up from the CheckMate 032 trial showed strong results with three different immunotherapy regimens involving nivolumab and ipilimumab in patients with previously treated metastatic urothelial carcinoma.
Experts discuss the implications of research that found PCI reduces brain metastases in stage III NSCLC, but does not improve overall survival.
Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving avelumab monotherapy.
Lenvatinib offers the highest published response rate to a targeted agent for patients with advanced neuroendocrine tumors, but the agent’s precise role in this setting remains in question.
The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma.
In general, NETs are considered an “immunological desert,” but a new study showed some promise for immunotherapy.
Researchers reported on differences in overall survival for LCT vs maintenance therapy/observation in oligometastatic NSCLC.
Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma?
A study in Thyroid evaluated the safety and efficacy of concurrent intensity-modulated radiation therapy and doxorubicin in thyroid cancer.